N/A
Completed N=38
To Compare Blephapad Combo vs Standard Treatment for Eyelid Cleansing in Bilateral Posterior Blepharitis
Bilateral Blepharitis (Disorder)
Source: ClinicalTrials.gov NCT03301844 ↗
Enrolled (actual)
38
Serious AEs
0.0%
Results posted
Dec 2019
Primary outcomePrimary: Percentage Change of the Total Score of the Grading Scales for Meibomian Gland Dysfunction (MGD) — -38.5; -29.9 percentage of change in the total score
Summary
The purpose of this study is to evaluate the efficacy of, and patient satisfaction with Blephapad Combo in the treatment of posterior blepharitis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage Change of the Total Score of the Grading Scales for Meibomian Gland Dysfunction (MGD) |
-38.5; -29.9 | — |
| SECONDARY Change of the Total Score of the Grading Scales for Meibomian Gland Dysfunction (Improved vs Not Improved) |
16; 15; 1; 2; 1; 1 | — |
| SECONDARY Number of Patients Preferring the Standard or the Study Treatment (i.e. Answers to a Specific Question on Patient Preference: Study Drug vs. Standard Treatment) |
12; 5 | 0.071 |
Eligibility Criteria
Inclusion Criteria
- Age > 40 years
- Male or female
- Diagnosis of bilateral posterior blepharitis
- Written informed consent of patient
Exclusion Criteria
- Treatment with topical ophthalmic drugs (artificial tears allowed)
- Ocular surgery in the previous 6 months
- Pregnant or breastfeeding women
- Alcohol abuse
- Psychiatric disorders
- Cognitive impairment that could affect evaluation of preferences
- Participation in other clinical studies in the last month
- Hypersensitivity to one or more components of the study products
Data sourced from ClinicalTrials.gov (NCT03301844). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.